Allergan Acular LS approved
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Allergan expects to launch Acular LS in the third quarter. The ketorolac tromethamine 0.4% ophthalmic solution clears FDA May 30 "for the reduction of ocular pain and burning/stinging following corneal refractive surgery." The "optimized formulation" joins Allergan's Acular (ketorolac 0.5%) family "used for a range of other conditions including post-surgical inflammation, pain, photophobia and ocular itch associated with seasonal allergies